The point of care diagnostics market share in 2026 is becoming an important part of modern healthcare as diagnostic testing continues to move closer to the location where patients receive treatment. Point-of-care testing (POCT) refers to diagnostic testing performed close to the site of patient care, allowing healthcare professionals to obtain results within a shorter turnaround time. These diagnostics are used across hospitals, physician offices, urgent care centers, retail clinics, and home settings for the detection and monitoring of various health conditions.

According to Fortune Business Insights, the global point of care diagnostics market size was valued at USD 32.87 billion in 2025 and is projected to grow from USD 34.47 billion in 2026 to USD 60.43 billion by 2034, exhibiting a CAGR of 7.27% during the forecast period. North America dominated the point of care diagnostics market with a market share of 35.6% in 2025.

The increasing prevalence of chronic and infectious diseases, combined with the ability of point-of-care diagnostics to provide rapid and accurate disease detection, is supporting market expansion. The growing emphasis on decentralized healthcare and the development of advanced diagnostic technologies are also encouraging adoption among healthcare providers and patients.

Point of Care Diagnostics Market Growth Driven by Rapid and Multiplex Testing

The increasing adoption of multiplex point-of-care testing platforms is supporting the growth of the market. Multiplex platforms enable the simultaneous identification of multiple pathogens or biomarkers from a single sample, helping reduce testing time and improve diagnostic efficiency. These technologies are particularly useful for healthcare facilities managing multiple disease burdens and for settings where rapid diagnosis is important.

Technological developments are also contributing to market expansion. Market participants and researchers are focusing on improving the capabilities of diagnostic platforms. Advanced infectious disease testing kits, urinalysis testing kits, hematology testing kits, and other products are increasing the availability of rapid testing solutions.

Connected Diagnostics and IoT Integration Create New Opportunities

The integration of Internet of Things (IoT) technologies with point-of-care diagnostics is creating opportunities for connected healthcare solutions. IoT-enabled platforms can transfer information from point-of-care devices to electronic health records and cloud-based systems. Such connectivity can support real-time patient monitoring, data analysis, remote patient management, telehealth services, and decentralized healthcare delivery.

The increasing use of connected diagnostic platforms is particularly relevant for rural and underserved areas where healthcare infrastructure may be limited. The market is also witnessing growing interest in home-based and self-testing solutions, while emerging technologies such as CRISPR-based diagnostics are attracting attention because of their speed, specificity, and suitability for point-of-care settings.

Market Drivers & Restraints:

The rising prevalence of chronic and infectious diseases is a major factor supporting the adoption of point-of-care diagnostics. Rapid testing capabilities allow healthcare professionals to obtain diagnostic information within a shorter period, supporting timely clinical decision-making. The growing adoption of multiplex platforms, technological advancements, and the expansion of decentralized healthcare are further contributing to market growth.

However, consistency and reliability of results remain important restraints. Variations in test performance can arise from device calibration, operator errors, and inadequate quality controls. Stringent regulatory requirements and different standards across geographic markets can also increase validation requirements, production timelines, and costs.

Market Competitive Landscape:

The global point of care diagnostics market is semi-consolidated, with several prominent companies accounting for a significant portion of the market. Key companies are focusing on research and development, technological advancements, product approvals, product launches, and portfolio expansion to strengthen their market positions.

F. Hoffmann-La Roche Ltd., Abbott, and Danaher Corporation are among the major companies operating in the market. Other prominent participants include EKF Diagnostics Holdings plc, Cardinal Health, Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, BD, bioMérieux SA, QuidelOrtho Corporation, and Bio-Rad Laboratories Inc. Companies are also exploring technologies such as artificial intelligence and nanotechnology to support the development of advanced point-of-care testing solutions.

Top Companies In The Market

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Abbott (U.S.)
  • EKF Diagnostics Holdings plc (U.K.)
  • Cardinal Health, Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Quest Diagnostics Incorporated (U.S.)
  • BD (U.S.)
  • bioMérieux SA (France)
  • QuidelOrtho Corporation (U.S.)
  • Bio-Rad Laboratories Inc. (U.S.)

Market Segments:

By Product (Blood Glucose Monitoring, Infectious Disease Testing, Cardiometabolic Disease Testing, Pregnancy & Fertility Testing, Hematology Testing, and Others)

By Sample (Blood, Nasal and Oropharyngeal Swabs, Urine, and Others)

By End-User (Hospital Bedside, Physician’s Office Lab, Urgent Care & Retail Clinics, and Home & Self testing)

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/point-of-care-diagnostics-market-101072 

Market Regional Insights:

North America dominated the market in 2025 with revenue of USD 11.69 billion, representing a 35.60% share of the global market. The regional market is projected to reach USD 12.29 billion in 2026. Advanced diagnostic penetration, funding availability, favorable reimbursement policies, product approvals, and investments in research and development are supporting regional growth.

Europe generated USD 10.56 billion in 2025, accounting for 32.10% of global revenue, and is estimated to reach USD 11.04 billion in 2026. The U.K. and Germany markets are valued at USD 2.23 billion and USD 2.46 billion, respectively, in 2026.

Asia Pacific accounted for 19.30% of the global market in 2025, reaching USD 6.35 billion, and is projected to reach USD 6.63 billion in 2026. Japan, China, and India are valued at USD 1.42 billion, USD 1.43 billion, and USD 1.87 billion, respectively, in 2026.

Future Market Scope:

The future of the point of care diagnostics market is expected to be shaped by connected diagnostic platforms, home-based testing, self-testing solutions, CRISPR-based technologies, and AI-enabled diagnostic systems. Increasing demand for rapid disease detection and decentralized healthcare is likely to support the adoption of point-of-care technologies across different healthcare settings. Continued research and development, product launches, regulatory approvals, and technological innovation are expected to influence the market through 2034.

Curious About Japan’s Market? Explore the Latest -Point of Care Diagnostics Market- Insights